ProfileGDS5678 / 1416772_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 73% 74% 74% 78% 73% 74% 79% 78% 81% 75% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.970575
GSM967853U87-EV human glioblastoma xenograft - Control 24.7232173
GSM967854U87-EV human glioblastoma xenograft - Control 34.8008474
GSM967855U87-EV human glioblastoma xenograft - Control 44.9678274
GSM967856U87-EV human glioblastoma xenograft - Control 55.3779378
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5923973
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7124174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5224479
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4094278
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7739381
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9065975
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8097474
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.929675
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9192475